Skip to main content

Table 1 Baseline characteristics of the study population

From: Monocyte/lymphocyte ratio predicts the severity of coronary artery disease: a syntax score assessment

Variable

Control Group

CAD Group

P value

(n = 162)

(n = 381)

Age (years)

55.41 ± 9.28

62.79 ± 9.52

<0.01

Male, n (%)

57(35%)

211(55%)

< 0.01

Family history, n (%)

20(12%)

55(14%)

0.52

Smoking, n (%)

46(28%)

186(49%)

< 0.01

DM, n (%)

25(15%)

139(36%)

< 0.01

HT, n (%)

85(52%)

291(76%)

< 0.01

HGB (g/L)

135.33 ± 15.87

136.53 ± 15.53

0.42

Platelet (109/L)

221.32 ± 51.31

211.14 ± 53.40

0.04

Leukocyte (109/L)

6.07(4.99–7.13)

6.60(5.60–7.70)

< 0.01

Neutrophil (109/L)

3.42(2.95–4.41)

4.24(3.40–5.10)

< 0.01

Monocyte (108/L)

3.02(2.51–3.62)

3.92(3.22–4.94)

< 0.01

Lymphocyte (109/L)

1.95(1.49–2.29)

1.70(1.36–2.19)

< 0.01

FBG (mmol/L)

5.35(4.93–5.88)

6.22(5.35–7.76)

< 0.01

TC (mmol/L)

4.84 ± 1.10

4.99 ± 1.13

0.15

TG (mmol/L)

1.51(1.06–2.23)

1.51(1.13–2.30)

0.36

LDL (mmol/L)

2.65(2.12–3.25)

2.73(2.23–3.43)

0.29

HDL (mmol/L)

1.16(0.94–1.39)

1.07(0.92–1.30)

0.03

SCr (μmol/L)

71.34(59.27–83.51)

75.96(64.82–89.80)

< 0.01

UA (μmol/L)

334.12 ± 93.41

335.56 ± 91.61

0.87

NLR

1.87(1.42–2.36)

2.47(1.86–3.34)

< 0.01

MLR

0.16(0.13–0.21)

0.23 (0.17–0.30)

< 0.01

Prior Medications

   

Aspirin, n (%)

133(82%)

320(84%)

0.59

Beta-blocker, n (%)

61(38%)

170(45%)

0.13

ACEI/ARB, n (%)

70(43%)

194(51%)

0.10

Stain, n (%)

129(80%)

317(83%)

0.32

  1. ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, DM diabetes mellitus, FBG fasting blood-glucose, HDL high-density lipoprotein, HGB Hemoglobin, HT hypertension, LDL low-density lipoprotein, MLR Monocyte to lymphocyte ratio, NLR neutrophil to lymphocyte ratio, SCr serum creatinine, TC total cholesterol, TG triglyceride, UA uric acid